HbA1c in CVD
5 Things a cardiologist needs to know about diabetes10' education - Feb. 14, 2018 - Prof Naveed Sattar, MD - University of Glasgow, United Kingdom
Prof Naveed Sattar discusses the value of HbA1c to diagnose T2DM, and how HbA1c levels are related to the risk of developing micro and macrovascular disease and the consequences thereof for choosing a HbA1c therapeutic target.
Video navigation menu
- The basis of HbA1c and its use in diagnosing T2DM 0:21
- HbA1c to predict development of microvascular disease and CV disease 3:13
- What do the ESC guidelines say about using HbA1c? 5:30
- Effects of lowering HbA1c 6:17
- Glycemic targets in relation to CV risk and in specific clinical situations 10:02
This educational video is part of a series called '5 Things a cardiologist needs to know about diabetes' that are aimed to guide cardiologists in management of patients with type 2 diabetes, since the cardiology practice is increasingly confronted with these patients. This series covers five topics that help cardiologists understand what is important when treating patients with diabetes, and what risks these patients face.
This recording was developed under auspices of PACE-cme. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-cme.
Naveed Sattar, MD is Professor of Cardiovascular and Medical Sciences, University of Glasgow. He is an academic (active clinically) experienced in biomarker studies/trials investigating the causes, prevention and management of diabetes, obesity and heart disease. He has authored or co-authored over 650 published papers, has received several national and international prizes for his research, and is in the top 1% of cited clinical academics in the world according to the Thomson Reuters 2016 Highly Cited Researcher list.
This educational series is funded by an unrestricted educational grant provided by Merck & Pfizer.